March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Fenofibrate Protects Retinal Müller cells from Oxidative Stress in a PPAR-alpha and AMPK-Dependent Mechanism
Author Affiliations & Notes
  • Elizabeth P. moran
    Cell Biology,
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
  • Yusuke Takahashi
    Endocrinology and Diabetes,
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
  • Ying Chen
    Endocrinology and Diabetes,
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
  • Jian-Xing Ma
    Physiology,
    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
  • Footnotes
    Commercial Relationships  Elizabeth P. moran, None; Yusuke Takahashi, None; Ying Chen, None; Jian-Xing Ma, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2239. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth P. moran, Yusuke Takahashi, Ying Chen, Jian-Xing Ma; Fenofibrate Protects Retinal Müller cells from Oxidative Stress in a PPAR-alpha and AMPK-Dependent Mechanism. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2239.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Clinical trials identified that the PPARα agonist fenofibrate inhibits diabetic retinopathy, but the mechanism is unknown. Preliminary reports suggest that fenofibrate’s protective effect is AMPK-dependent and PPARα-independent in retinal endothelial cells, but evidence are circumstantial, and no downstream target of AMPK has been proposed. Furthermore, the effect of fenofibrate on retinal Müller cells, which are critical in the development of DR, is unknown.

 
Methods:
 

We used 4-Hydroxynonenal to induce oxidative stress in human Müller cells and quantified fenofibrate protection using an MTT assay. We determined its dependence on PPARα and AMPK using small molecule inhibition. We used western blotting to determine expression of UCP2 and activation of AMPK and used adenoviral PPARα overexpression to determine whether these effects were a consequence of PPARα activation.

 
Results:
 

We identified that fenofibrate-mediated cytoprotection is AMPK and PPARα-dependent (fig 1). Moreover, both fenofibrate and PPARα overexpression activate AMPK(fig 2). We found that the mitochondrial uncoupling protein UCP2 is upregulated (fig 2).

 
Conclusions:
 

Taken together, our data suggest that fenofibrate’s protective effect is AMPK and PPARα dependent. Furthermore, because both fenofibrate and PPARα overexpression activate AMPK, this event may be PPARα-specific. We have also identified for the first time that both fenofibrate and PPARα upregulate UCP2, which is known to inhibit neurodegeneration and also diabetic complications. UCP2 is stabilized by active AMPK, and we hypothesize that fenofibrate AMPK activation may be responsible for UCP2 upregulation.  

 

 
Keywords: diabetic retinopathy • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×